Robert W. Baird analyst Jeff Johnson reiterated a Buy rating on Henry Schein (HSIC – Research Report) on November 5 and set a price ...

Henry Schein (HSIC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael ...

Henry Schein posts Q3 adjusted EPS of $1.23, topping forecasts, while sales of $3.17 billion fall short. The company revises ...

Dental supply company Henry Schein reported total net sales of $3.2 billion during the third quarter of 2024, according to a Nov. 5 financial report. Here are eight things to know: 1. Third-quarter ...

Analysts' ratings for Henry Schein (NASDAQ ... is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins.

Dental products distributor Henry Schein beat third-quarter profit estimates on Tuesday, as a series of cost-saving measures helped counter tepid demand and slow recovery from a cyberattack it ...

Henry Schein is a Fortune 500 company and one of the global leaders in its industry, providing healthcare solutions, as well as the distribution of medical, dental, and veterinary supplies.